Anti-CD19 CAR T-Cell Therapy Demonstrates Feasibility Among Patients With MCL With Secondary CNS Involvement
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy demonstrated feasibility among patients with mantle cell lymphoma (MCL) with secondary central nervous system (SCNS) involvement, according to findings published in the British Journal of Haematology.
According to Christine E Ryan, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, and coauthors, “Data describing outcomes of chimeric antigen receptor (CAR) T-cell therapy in patients with secondary central nervous system (SCNS) involvement of mantle cell lymphoma (MCL) are limited.” This lack of data was the impetus for this study, which aimed to evaluate the efficacy and safety of anti-CD19 CAR T-cell therapy among this patient population.
In this study, 10 patients with MCL and SCNS involvement were enrolled and treated with anti-CD19 CAR T-cell therapy at 3 United States academic centers. Objective response rates, progression-free survival, and safety were observed as endpoints. Results indicated that 86% of patients exhibited objective responses in the central nervous system, and 90% demonstrated responses systematically following therapy. The 1-year progression-free survival rate was 47%.
In terms of safety, immune-effector-cell-associated neurotoxicity syndrome occurred in 7 patients. Among them, 2 patients had cases of grade 1 severity, and 5 had cases of grade 3 severity.
As endpoints were met, Dr Ryan and coauthors concluded, “Our results suggest that anti-CD19 CAR T-cell therapy in this setting is feasible and additional data regarding neurotoxicity in this population may be warranted.”
Source:
Ryan CE, Zon RL, Redd R, et al. Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement. Br J Haematol. Published online: August 16, 2023. doi:10.1111/bjh.19037
